ADL
WINT

Asset Dedication LLC’s Windtree Therapeutics Inc WINT Stock Holding History

Asset Dedication LLC’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5
Closed – – 714
2015
Q4 		$0 Buy
+5
New +$21 ﹤0.01% 709

Other funds holding WINT

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Asset Dedication LLC's WINT Position: Q1 2016 in Review

Asset Dedication LLC sold out of Windtree Therapeutics Inc (WINT) in Q1 2016, closing a stake of 5 shares.

Asset Dedication LLC first reported a position in WINT in Q4 2015 and held it in 1 quarter. The position peaked at $0 in Q4 2015. 34 funds tracked by Wall St. Rank hold WINT as of Q1 2016.

  • Asset Dedication LLC reported no remaining Windtree Therapeutics Inc position as of Q1 2016 after selling out during the quarter.
  • Asset Dedication LLC sold 5 Windtree Therapeutics Inc shares in Q1 2016.
  • Asset Dedication LLC first reported a position in Windtree Therapeutics Inc in Q4 2015 and held it in 1 quarter.
  • Asset Dedication LLC's Windtree Therapeutics Inc position peaked at $0 in Q4 2015.
  • 34 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q1 2016.

Based on Asset Dedication LLC's 13F filing for Q1 2016, filed 27 Apr 2016.